BioStock: Status report Xintela - Integrins marking the future
Xintela was founded in 2009 by Evy Lundgren-Åkerlund based on her research and discoveries on the properties of the marker protein integrin α10β1. Since then, the company has developed new treatments in both cell therapy and oncology with their well-developed technology platform and broad patent portfolio as a basis. BioStock has now published a status report on Xintela.
Read the full Xintela status report at biostock.se:
This is a pressrelease from BioStock Connecting - Innovation & Capital. https://www.biostock.se/